Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1891-1900, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kauppinen, R.
Right arrow Articles by von und zu Fraunberg, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kauppinen, R.
Right arrow Articles by von und zu Fraunberg, M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2002;48:1891-1900.)
© 2002 American Association for Clinical Chemistry, Inc.

Molecular and Biochemical Studies of Acute Intermittent Porphyria in 196 Patients and Their Families

Raili Kauppinena1 and Mikael von und zu Fraunberg1

1 Department of Medicine, Division of Endocrinology, University Hospital of Helsinki, 00029 HUS Helsinki, Finland.

aAddress correspondence to this author at: Department of Medicine, University Central Hospital of Helsinki, Biomedicum-Helsinki, Box 700, 00029 HUS Helsinki, Finland. E-mail raili.kauppinen{at}hus.fi.

Background: Acute intermittent porphyria (AIP) is a metabolic disease with clinical manifestations that mimic other abdominal, neurologic, or mental crises. We studied the diagnostic accuracy of current laboratory tests during an acute attack and in remission.

Methods: Since 1966, we have studied all known Finnish AIP patients (n = 196) and their families (n = 45) and identified the porphobilinogen deaminase (PBGD) mutation in each family. Diagnoses or exclusions of AIP were based on clinical data (including family history), biochemical tests, and in 239 cases, mutation testing. We retrospectively evaluated the diagnostic accuracy of erythrocyte PBGD activity, urinary excretion of porphobilinogen (PBG) and {delta}-aminolevulinic acid, and urinary and fecal excretion of porphyrins in these patients.

Results: Measurement of urinary PBG identified all 35 AIP patients studied during an acute attack. The mean excretion of PBG was 50-fold above the reference interval, although the intraindividual increases were modest (1.6- to 4.0-fold). In the mutation-screened population, urinary PBG analysis identified only 85% of 81 AIP patients studied during remission, but by ROC curve analysis it was nonetheless the best of the biochemical tests. It was increased <=2-fold in 29% of healthy relatives. Erythrocyte PBGD activity was decreased in only 84% of AIP patients, with results within the reference interval mainly in the variant form of AIP; it was decreased in 23% of healthy relatives.

Conclusions: Measurement of urinary PBG is the best biochemical test for AIP, although it is unspecific and does not distinguish AIP from other acute porphyrias. Because the acute increase in PBG is often modest, the medical history, signs, and symptoms must be evaluated carefully during an acute attack. In addition, because biochemical analyses often remain indeterminate in remission, mutation analysis is needed to exclude or confirm the diagnosis of AIP.




The following articles in journals at HighWire Press have cited this article:


Home page
 Ann Clin BiochemHome page
A. Pfafflin
Remarks on the acute intermittent porphyria
Ann Clin Biochem, July 1, 2009; 46(4): 347 - 348.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. K. Aarsand, H. Boman, and S. Sandberg
Familial and Sporadic Porphyria Cutanea Tarda: Characterization and Diagnostic Strategies
Clin. Chem., April 1, 2009; 55(4): 795 - 803.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. K. Aarsand, P. H. Petersen, and S. Sandberg
Estimation and Application of Biological Variation of Urinary {delta}-Aminolevulinic Acid and Porphobilinogen in Healthy Individuals and in Patients with Acute Intermittent Porphyria.
Clin. Chem., April 1, 2006; 52(4): 650 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Sandberg and G. H. Elder
Diagnosing Acute Porphyrias
Clin. Chem., May 1, 2004; 50(5): 803 - 805.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
B. Lumbreras-Lacarra, J. M. Ramos-Rincon, and I. Hernandez-Aguado
Methodology in Diagnostic Laboratory Test Research in Clinical Chemistry and Clinical Chemistry and Laboratory Medicine
Clin. Chem., March 1, 2004; 50(3): 530 - 536.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.